cilostazol has been researched along with Brain Vascular Disorders in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population." | 7.85 | Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. ( Chang, YH; Chien, CY; Tai, SY; Yang, YH, 2017) |
| "Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding." | 3.88 | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database. ( Alzamora, M; Forés, R; Giner-Soriano, M; Heras, A; Marsal, JR; Morros, R; Pera, G; Real, J; Ribes, E; Serna, MC, 2018) |
| " We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population." | 3.85 | Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. ( Chang, YH; Chien, CY; Tai, SY; Yang, YH, 2017) |
| "One possible cause of stent thrombosis is an insufficient effect of clopidogrel." | 3.77 | Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. ( Behr, T; Behr, W; Kuch, B; von Scheidt, W, 2011) |
| "Cilostazol was orally administered for 209 days on average." | 2.69 | [Effects of long-term administration of cilostazol on chronic cerebral circulatory insufficiency--with special reference to cerebral blood flow and clinical symptoms]. ( Anegawa, S; Furukawa, Y; Hayashi, T; Katsuragi, M; Tomokiyo, M; Torigoe, R, 1998) |
| "Cilostazol is a potent type III phosphodiesterase inhibitor with pharmacological effects that include vasodilatation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth." | 2.44 | Cilostazol in the management of vascular disease. ( Dalainas, I, 2007) |
| "6 months, major adverse cardiac and cerebrovascular events (MACCE) occurred in 43 patients (17." | 1.39 | Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013) |
| "Cilostazol is an antiplatelet drug often used in Asia; however, it is rarely used in the western hemisphere, particularly for stroke patients." | 1.37 | Cilostazol: a drug particularly effective for Asians? ( Kim, JS; Shinohara, Y, 2011) |
| "8% in the 50 mg/day (once daily), 100 mg/day (50 mg twice a day), 150 mg/day (50 mg three times a day) and 200 mg/day (100 mg twice a day) dosage groups, respectively." | 1.27 | Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. ( Mase, K; Yasunaga, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Real, J | 1 |
| Serna, MC | 1 |
| Giner-Soriano, M | 1 |
| Forés, R | 1 |
| Pera, G | 1 |
| Ribes, E | 1 |
| Alzamora, M | 1 |
| Marsal, JR | 1 |
| Heras, A | 1 |
| Morros, R | 1 |
| Lee, HJ | 1 |
| Yu, CW | 1 |
| Hwang, HK | 1 |
| Choi, RK | 1 |
| Park, JS | 1 |
| Li, H | 1 |
| Ro, YM | 1 |
| Ueda, H | 1 |
| Kido, A | 1 |
| Matsuhisa, S | 1 |
| Asawa, K | 1 |
| Yoshida, N | 1 |
| Tsujimoto, M | 1 |
| Sasaki, Y | 1 |
| Kuga, Y | 1 |
| Yamasaki, M | 1 |
| Ueda, K | 1 |
| Shinohara, S | 1 |
| Nishida, Y | 1 |
| Tai, SY | 1 |
| Chien, CY | 1 |
| Chang, YH | 1 |
| Yang, YH | 1 |
| Goto, S | 1 |
| Toda, E | 1 |
| Rhee, SY | 1 |
| Kim, YS | 1 |
| Chon, S | 1 |
| Oh, S | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Yoshikawa, H | 1 |
| Suzuki, M | 1 |
| Hashimoto, G | 1 |
| Otsuka, T | 1 |
| Sugi, K | 1 |
| Behr, T | 1 |
| Kuch, B | 1 |
| Behr, W | 1 |
| von Scheidt, W | 1 |
| Kim, JS | 1 |
| Shinohara, Y | 1 |
| Takahashi, K | 1 |
| Mikuni, M | 1 |
| Sakurai, H | 1 |
| Hanyu, H | 1 |
| Sato, T | 1 |
| Kume, K | 1 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Iwamoto, T | 1 |
| Dalainas, I | 1 |
| Lee, JH | 1 |
| Park, SY | 1 |
| Shin, HK | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Torigoe, R | 1 |
| Hayashi, T | 1 |
| Anegawa, S | 1 |
| Furukawa, Y | 1 |
| Tomokiyo, M | 1 |
| Katsuragi, M | 1 |
| Uehara, S | 1 |
| Hirayama, A | 1 |
| Yasunaga, K | 2 |
| Mase, K | 2 |
2 reviews available for cilostazol and Brain Vascular Disorders
| Article | Year |
|---|---|
Cilostazol in the management of vascular disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; | 2007 |
Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
Topics: Cerebrovascular Disorders; Chronic Disease; Cilostazol; Clinical Trials as Topic; Humans; Ischemic A | 2008 |
3 trials available for cilostazol and Brain Vascular Disorders
12 other studies available for cilostazol and Brain Vascular Disorders
| Article | Year |
|---|---|
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Agents; Cerebrovascular Disorders; Cilostazol; | 2018 |
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb | 2013 |
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Cilostazol; Cohort Studies; Dementia; Fem | 2017 |
Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention.
Topics: Asia; Cerebral Hemorrhage; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Coronary Disease; Eur | 2009 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Impact of cilostazol on left ventricular geometry and function: assessment by tissue Doppler imaging and two-dimensional speckle-tracking echocardiography.
Topics: Administration, Oral; Aged; Blood Pressure; Cerebrovascular Disorders; Cilostazol; Comorbidity; Echo | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascula | 2011 |
Cilostazol: a drug particularly effective for Asians?
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders | 2011 |
[Augmentation therapy with cilostazol for the intractable geriatric major depressive disorder patients with deep white matter hyperintensities on T2-weighted brain MRI].
Topics: Aged; Brain; Cerebrovascular Disorders; Cilostazol; Depressive Disorder, Major; Female; Humans; Magn | 2012 |
Effects of cilostazol on platelet function.
Topics: Adult; Aged; Aged, 80 and over; Azoles; Blood Platelets; Cerebrovascular Disorders; Cilostazol; Fema | 1989 |
Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease.
Topics: Administration, Oral; Azoles; Bleeding Time; Blood Platelets; Cerebrovascular Disorders; Cilostazol; | 1985 |
Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
Topics: Administration, Oral; Adult; Aged; Azoles; Cerebrovascular Disorders; Cilostazol; Female; Fibrinolyt | 1985 |